500213-34-3

Basic information

• Product Name: 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]carb onyl]-, 1,1-dimethylethyl ester, (3S)-
• CAS NO: 500213-34-3
• Molecular Formula: C25H30N2O5
• Molecular Weight: 438.524
• Mol File: 500213-34-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]carb onyl]-, 1,1-dimethylethyl ester, (3S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]carb onyl]-, 1,1-dimethylethyl ester, (3S)-(500213-34-3)
• EPA Substance Registry System: 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]carb onyl]-, 1,1-dimethylethyl ester, (3S)-(500213-34-3)

Safety Data

• Hazardous Substances Data: 500213-34-3(Hazardous Substances Data)

Upstream product

• 77497-95-1 (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride 
• 63-91-2 L-phenylalanine 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 115962-35-1 (3S)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinole-3-carboxylic acid 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 

Downstream Products

• 1034535-58-4 N-(3S-2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-phenylalanine 
• 1338586-83-6 (S)-N-((S)-1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride 
• 681254-34-2 2-benzyloxycarbonylamino-3-[2-({2-[2-{[1-(2-tert-butoxycarbonylamino-4-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-(4-hydroxy-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl}-amino)-3-phenyl-propionyloxy]-butyric acid methyl ester 
• 681254-26-2 (2S,3R)-2-Benzyloxycarbonylamino-3-[(S)-2-({(S)-2-[(S)-2-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl}-amino)-3-phenyl-propionyloxy]-butyric acid methyl ester 
• 681254-18-2 (2S,3R)-2-Benzyloxycarbonylamino-3-[(S)-2-({(S)-2-[(S)-2-tert-butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl}-amino)-3-phenyl-propionyloxy]-butyric acid methyl ester 
• 808771-84-8 (S)-2-({(S)-2-[(S)-2-[(S)-2-tert-Butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl}-amino)-3-phenyl-propionic acid methyl ester 
• 808771-82-6 (S)-2-({(S)-2-[(S)-2-[(S)-2-tert-Butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-3-(4-hydroxy-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl}-amino)-3-phenyl-propionic acid methyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors

A series of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were designed, synthesized and assayed for their activities against aminopeptidase N (APN/CD13) and MMP-2. The results showed that most compounds exhibited higher inhibitory activities against APN than that of MMP-2. Within this series, compound 12h (IC50 = 6.28 ± 0.11 μM) showed similar inhibitory activities compared with Bestatin (IC50 = 5.55 ± 0.01 μM), and it could be used as novel lead compound for the future APN inhibitors development as anticancer agents.

A class of novel N-(3S-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-l-amino acid derivatives: their synthesis, anti-thrombotic activity evaluation, and 3D QSAR analysis

To find new anti-thrombotic agents, a natural amino acid was introduced into the 3-position of anti-platelet aggregation active 3S-tetrahydroisoquinoline-3-carboxylic acid (THIQA), and 20 novel dipeptide derivatives, 3S-tetrahydroisoquinoline-3-carboxyamino acids (6a-t), targeting the intestinal peptide transport system were provided. In vitro anti-platelet aggregation assay of 6a-t indicated that their potencies of inhibiting adenosine diphosphate (ADP), arachidonic acid (AA), platelet-activating factor (PAF), and thrombin (TH) induced platelet aggregations were higher than that of THIQA, and the in vivo anti-thrombotic assay of 6a-t indicated that their potencies of inhibiting thrombogenesis in rats were also higher than that of THIQA. According to MFA based Cerius2 QSAR module, using training/test set of 6a,b,d,g-p/6c,e,f,q and training/test set of 6a-p/6q-t, two equations (r, 0.984 and 0.996) correlating the structures with in vitro or in vivo activity of 6a-t were established.

A progressive synthetic strategy for class B synergimycins

Described are the syntheses of four macrocyclic peptides that are the core structure of class B synergimycins, and the synthesis of a final class B derivative. Our synthetic route to these synergimycin derivatives allows the incorporation of amino acid su